AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20167903 — intervention group
Group type: COMPARATOR
Intervention: Health-promotion control intervention
Number of subjects: 1707
Study 18417963 — intervention group
Group type: EXPERIMENTAL
Intervention: Danqi Piantan Jiaonang (DPJ) 4 capsules (0.4 g/capsule) taken orally 2 times 6 hours apart
Number of subjects: 42
Study 18417963 — intervention group
Group type: COMPARATOR
Intervention: Combination of aspirin 300 mg and 2 doses of DPJ 4 capsules taken 6 hours apart
Number of subjects: 42
Study 18417963 — intervention group
Group type: EXPERIMENTAL
Intervention: Danqi Piantan Jiaonang (DPJ) 4 capsules taken orally 3 times a day for 1 month
Number of subjects: 42
Study 15783004 — intervention group
Group type: EXPERIMENTAL
Intervention: Dai‐ken‐chu‐to and Keish‐bukuryo‐gan (7.5g and 6.0g respectively)
Number of subjects: 66
Study 15783004 — intervention group
Group type: COMPARATOR
Intervention: Control (no herbal medicine)
Number of subjects: 66
Study 12431854 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (P4) replacement in women
Number of subjects: 0
Study 12431854 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) replacement in women
Number of subjects: 0
Study 12431854 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) replacement in men
Number of subjects: 0
Study 12431854 — intervention group
Group type: COMPARATOR
Intervention: Hypogonadism (leuprolide-induced)
Number of subjects: 0
Study 10495595 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based interventions for improving care for depression
Number of subjects: 46
Study 8739165 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 29
Study 8739165 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin
Number of subjects: 29
Study 1299814 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 30
Study 1299814 — intervention group
Group type: COMPARATOR
Intervention: Netilmicin
Number of subjects: 30
Study 6237085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroimidazole radiosensitizers
Number of subjects: 0
Study 6237085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sural nerve biopsies
Number of subjects: 0
Study 30167807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment (< 120 mmHg) in the low-SBP group
Number of subjects: 9361
Study 30167807 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment (< 140 mmHg) in the low-SBP group
Number of subjects: 9361
Study 30167807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure treatment (< 120 mmHg) in the high-SBP group
Number of subjects: 9361
Study 30167807 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure treatment (< 140 mmHg) in the high-SBP group
Number of subjects: 9361
Study 29961053 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex 19G needle
Number of subjects: 78
Study 29961053 — intervention group
Group type: COMPARATOR
Intervention: 22G needle
Number of subjects: 78
Study 26894640 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapatellar (SP) tibial nail insertion
Number of subjects: 41
Study 26894640 — intervention group
Group type: COMPARATOR
Intervention: Infrapatellar (IP) tibial nail insertion
Number of subjects: 41
Study 26894640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SP and IP)
Number of subjects: 41
Study 25238874 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Instrument for Screening in the Community (RISC)
Number of subjects: 803
Study 25238874 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS)
Number of subjects: 803
Study 25238874 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index
Number of subjects: 803
Study 25238874 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated Mental Test Score (AMTS)
Number of subjects: 803
Study 22326435 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 135
Study 22326435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 20816187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination inhaler (125 microg fluticasone dipropionate and 25 microg salmeterol, 2 actuations twice daily)
Number of subjects: 111
Study 20816187 — intervention group
Group type: COMPARATOR
Intervention: Separate inhalers (125 microg fluticasone dipropionate and 25 microg salmeterol, 2 actuations twice daily)
Number of subjects: 111
Study 20816187 — intervention group
Group type: COMPARATOR
Intervention: Combination inhaler vs. fluticasone
Number of subjects: 111
Study 20816187 — intervention group
Group type: COMPARATOR
Intervention: Combination inhaler vs. salmeterol
Number of subjects: 111
Study 20816187 — intervention group
Group type: EXPERIMENTAL
Intervention: LABA monotherapy
Number of subjects: 111
Study 18077927 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine oral solution (20 mg/20 drops)
Number of subjects: 48
Study 18077927 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine tablets (20 mg)
Number of subjects: 48
Study 15579724 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable asthma
Number of subjects: 71
Study 15579724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectasis
Number of subjects: 71
Study 15579724 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute asthma exacerbation
Number of subjects: 71
Study 15579724 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma severity pattern
Number of subjects: 71
Study 15579724 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 71
Study 12087641 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartPower! Program
Number of subjects: 58
Study 12087641 — intervention group
Group type: COMPARATOR
Intervention: Standard health education curriculum
Number of subjects: 58
Study 9796960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mesna
Number of subjects: 25
Study 9796960 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mesna
Number of subjects: 25
Study 9796960 — intervention group
Group type: EXPERIMENTAL
Intervention: Both i.v. and oral mesna
Number of subjects: 25
Study 7607199 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction (10-min static plantar flexion of one calf at 200 N)
Number of subjects: 7
Study 7607199 — intervention group
Group type: COMPARATOR
Intervention: Passive calf muscle stretch (10 min at the same load of 200 N)
Number of subjects: 7
Study 2650897 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg.kg‐1 rectal methohexitone
Number of subjects: 60
Study 2650897 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg.kg‐1 rectal methohexitone
Number of subjects: 60
Study 2650897 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg.kg‐1 rectal methohexitone
Number of subjects: 60
Study 2650897 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 rectal methohexitone
Number of subjects: 60
Study 2650897 — intervention group
Group type: COMPARATOR
Intervention: 15 mg.kg‐1 and 20 mg.kg‐1 rectal methohexitone
Number of subjects: 60
Study 1096630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% tetracycline ointment
Number of subjects: 234
Study 1096630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% rifampicin ointment
Number of subjects: 234
Study 1096630 — intervention group
Group type: COMPARATOR
Intervention: 5% boric acid ointment
Number of subjects: 234
Study 31722055 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Number of subjects: 136
Study 31722055 — intervention group
Group type: COMPARATOR
Intervention: Plain angioplasty balloon
Number of subjects: 136
Study 29321180 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 379
Study 29321180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 379
Study 28027761 — intervention group
Group type: EXPERIMENTAL
Intervention: New imaging technology (after upgrade)
Number of subjects: 108
Study 28027761 — intervention group
Group type: COMPARATOR
Intervention: Precursor technology (before upgrade)
Number of subjects: 108
Study 25732875 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (n=31)
Number of subjects: 85
Study 25732875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=29)
Number of subjects: 85
Study 25732875 — intervention group
Group type: COMPARATOR
Intervention: Control (n=25)
Number of subjects: 85
Study 22517125 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar guided polypropylene mesh kit repair
Number of subjects: 353
Study 20946751 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine
Number of subjects: 498
Study 20946751 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 498
Study 20946751 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled spirits
Number of subjects: 498
Study 18547287 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks and intranasal budesonide for 12 weeks (treatment group)
Number of subjects: 32
Study 18547287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32
Study 16299871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg per day
Number of subjects: 35
Study 16299871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg per day
Number of subjects: 35
Study 16299871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment for 1 year after 2 years of treatment)
Number of subjects: 35
Study 16299871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 35
Study 12006794 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (5 mg)
Number of subjects: 45
Study 12006794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 45
Study 12006794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 45
Study 12006794 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.5 mg) administered to seven benzodiazepine-treated patients
Number of subjects: 45
Study 12006794 — intervention group
Group type: COMPARATOR
Intervention: Nonpremedicated controls
Number of subjects: 45
Study 10337606 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple chemical sensitivity (MCS) group
Number of subjects: 63
Study 10337606 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma group
Number of subjects: 63
Study 10337606 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 63
Study 10337606 — intervention group
Group type: EXPERIMENTAL
Intervention: MCS group
Number of subjects: 63
Study 7473011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) 10 mg/ml for 1 minute
Number of subjects: 0
Study 7473011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) 10 mg/ml for 4 minutes
Number of subjects: 0
Study 7473011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) 100 mg/ml for 1 minute
Number of subjects: 0
Study 7473011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCl (TTC) 100 mg/ml for 4 minutes
Number of subjects: 0
Study 7473011 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile saline for 1 minute)
Number of subjects: 0
Study 1955166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose given by mouth during gastric phases I, II, III
Number of subjects: 6
Study 1955166 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose infused duodenally during duodenal phases I, II, III
Number of subjects: 6
Study 6161804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prophylaxis with broad spectrum tetracycline (Group B)
Number of subjects: 118
Study 6161804 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion prophylaxis (Group C)
Number of subjects: 118
Study 6161804 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Group A)
Number of subjects: 118
Study 29981096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplements
Number of subjects: 249
Study 29981096 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smoking, higher education, higher income, food security, increased body mass index
Number of subjects: 249
Study 29981096 — intervention group
Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 249
Study 27416975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin maintenance therapy (intravesical instillations once a week for 3 weeks at 3, 6, 12 and 18 months after induction)
Number of subjects: 95
Study 27416975 — intervention group
Group type: COMPARATOR
Intervention: Non-maintenance group (bacillus Calmette-Guérin induction therapy only)
Number of subjects: 95
Study 27416975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin maintenance therapy
Number of subjects: 95
Study 24399101 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 104
Study 24399101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (CT)
Number of subjects: 104
Study 24399101 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 104
Study 22170807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone furoate
Number of subjects: 25
Study 22170807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19875277 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal tulobuterol (2mg) combined with inhaled tiotropium (18microg)
Number of subjects: 103
Study 19875277 — intervention group
Group type: COMPARATOR
Intervention: Inhaled tiotropium (18microg)
Number of subjects: 103
Study 18412932 — intervention group
Group type: EXPERIMENTAL
Intervention: MXR 1500 mg once daily after dinner
Number of subjects: 150
Study 18412932 — intervention group
Group type: COMPARATOR
Intervention: MIR 500 mg thrice daily after meals
Number of subjects: 150
Study 18412932 — intervention group
Group type: EXPERIMENTAL
Intervention: MXR or MIR
Number of subjects: 150
Study 16319559 — intervention group
Group type: EXPERIMENTAL
Intervention: Online programme
Number of subjects: 15
Study 16319559 — intervention group
Group type: COMPARATOR
Intervention: Computer‐assisted programme
Number of subjects: 15
Study 16319559 — intervention group
Group type: COMPARATOR
Intervention: Therapist‐administered programme
Number of subjects: 15
Study 12566477 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplement (200 micro g) for 20 weeks
Number of subjects: 189
Study 12566477 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 20 weeks
Number of subjects: 189
Study 10232443 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithioerythritol (DTE)
Number of subjects: 0
Study 10232443 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 0
Study 8714324 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 10
Study 1721787 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug (quinine/quinidine/cinchonine) high dose regimen
Number of subjects: 0
Study 1721787 — intervention group
Group type: COMPARATOR
Intervention: Combined drug (quinine/quinidine/cinchonine) low dose regimen
Number of subjects: 0
Study 1721787 — intervention group
Group type: COMPARATOR
Intervention: Quinine alone
Number of subjects: 0
Study 6416399 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 100 mg administered eight hourly
Number of subjects: 0
Study 6416399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 0
Study 6416399 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rectal indomethacin and cryoanalgesia
Number of subjects: 0
Study 6416399 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular opiate analgesia
Number of subjects: 0
Study 31063503 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP)
Number of subjects: 1320
Study 31063503 — intervention group
Group type: COMPARATOR
Intervention: Control (two doses of sulfadoxine-pyrimethamine)
Number of subjects: 1320
Study 27631091 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg)
Number of subjects: 665
Study 27631091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665
Study 26458336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol treatment after 90 days
Number of subjects: 130
Study 26458336 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (UA) levels
Number of subjects: 130
Study 25073942 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression with Wallis implant
Number of subjects: 60
Study 25073942 — intervention group
Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 60
Study 21785897 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g/kg of charcoal-barbecued meat (experiment 1)
Number of subjects: 0
Study 21785897 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/kg of charcoal-barbecued meat (experiment 2)
Number of subjects: 0
Study 21785897 — intervention group
Group type: COMPARATOR
Intervention: Background urinary 3-OHBaP
Number of subjects: 0
Study 19735233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 4270
Study 19735233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 60 mg
Number of subjects: 4270
Study 19735233 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 4270
Study 19735233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4270
Study 19735233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR (all doses)
Number of subjects: 4270
Study 19735233 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 4270
Study 17718360 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp corners
Number of subjects: 0
Study 17718360 — intervention group
Group type: COMPARATOR
Intervention: Shallow corners
Number of subjects: 0
Study 15843763 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant + fluvoxamine (STIM/FLV)
Number of subjects: 25
Study 15843763 — intervention group
Group type: COMPARATOR
Intervention: Stimulant + placebo (STIM/PL)
Number of subjects: 25
Study 12093599 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1 mg)
Number of subjects: 20
Study 12093599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10597811 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior ankle-foot orthosis (AFO)
Number of subjects: 24
Study 7733543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 30
Study 7733543 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 30
Study 2254498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction at the beginning of each session
Number of subjects: 60
Study 2254498 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving relaxation and breathing exercises
Number of subjects: 60
Study 2254498 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly susceptible, hypnotically treated women
Number of subjects: 60
Study 7001491 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg proquazone per day
Number of subjects: 36
Study 7001491 — intervention group
Group type: COMPARATOR
Intervention: 900 mg proquazone per day
Number of subjects: 36
Study 31090181 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with Powerbreathe®, performing eight series of 2 minutes each at 60% of maximum inspiratory pressure.
Number of subjects: 26
Study 31090181 — intervention group
Group type: COMPARATOR
Intervention: Control group performing the same training protocol but with the load maintained at 9 cmH2O.
Number of subjects: 26
Study 28235523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 28235523 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA) with propofol-remifentanil
Number of subjects: 80
Study 25499170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks post-operative BRT test
Number of subjects: 38
Study 25499170 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks post-operative BRT test
Number of subjects: 38
Study 25499170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative BRT test
Number of subjects: 38
Study 25675721 — intervention group
Group type: EXPERIMENTAL
Intervention: Meldonium 1000 mg/day for 3 months during winter
Number of subjects: 49
Study 25675721 — intervention group
Group type: COMPARATOR
Intervention: Control group (K)
Number of subjects: 49
Study 22473650 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotion condition
Number of subjects: 28
Study 22473650 — intervention group
Group type: COMPARATOR
Intervention: Neutral emotion condition
Number of subjects: 28
Study 19422623 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of paroxetine
Number of subjects: 80
Study 19422623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17226851 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 21
Study 15986766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole/Clindamycin
Number of subjects: 23
Study 15986766 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole/Nistatine
Number of subjects: 23
Study 11260907 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery for colorectal cancer
Number of subjects: 0
Study 11260907 — intervention group
Group type: COMPARATOR
Intervention: Conventional open procedures
Number of subjects: 0
Study 9884857 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 mg intravenously
Number of subjects: 63
Study 9884857 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 63
Study 8021700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinine hydrobromide (300 mg/day)
Number of subjects: 20
Study 8021700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2605070 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. omeprazole 40 mg 1 h before surgery
Number of subjects: 87
Study 2605070 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. omeprazole 40 mg 3 h before surgery
Number of subjects: 87
Study 2605070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 163625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive psychosocial inhospital treatment (mean length of stay 30 days)
Number of subjects: 58